International Society of Liquid Biopsy shared a post on X about a recent article by Aurore Perrot et al. published in NEJM:
“MRD-guided strategy in Myeloma
MIDAS Phase 3 trial published in NEJM
Key findings:
In MRD⁻ pts (10⁻⁵), ASCT vs Isa-KRd to no significant difference in MRD⁻ (10⁻⁶) before maintenance
In MRD⁺ pts, tandem ASCT vs single ASCT to no added benefit
MRD status can personalize post-induction therapy — but more is not always better.”
Title: Measurable Residual Disease–Guided Therapy in Newly Diagnosed Myeloma
Authors: Aurore Perrot, Jérôme Lambert, Cyrille Hulin, Andrea Pieragostini, Lionel Karlin, Bertrand Arnulf, Philippe Rey, Laurent Garderet, Margaret Macro, Martine Escoffre-Barbe, Julie Gay, Thomas Chalopin, Romain Gounot, Jean-Marc Schiano, Mohamad Mohty, Xavier Leleu, Salomon Manier, Clara Mariette, Carine Chaleteix, Thorsten Braun, Bernard De Prijck, Hervé Avet-Loiseau, Jean-Yves Mary, Jill Corre, Philippe Moreau, Cyrille Touzeau
Read the Full Article on The New England Journal of Medicine
More posts featuring International Society of Liquid Biopsy.
